Early-stage breast cancer conservative treatment: high-dose-rate brachytherapy boost in a single fraction of 700 cGy to the tumour bed.

Abstract

BACKGROUND AND PURPOSE Conservative treatment represents the current therapy for early-stage breast cancer. When risk factors for local relapse exist, a tumour bed boost is required. Retrospectively, we evaluated the prognostic factors influencing local recurrence (LR), overall survival (OS) and disease-free survival (DFS). MATERIAL AND METHODS After conservative treatment, 210 patients received a single-dose HDR brachytherapy (HDRBT) boost between June 1996 and December 2005. Mean age was 57 years; 75% had invasive ductal carcinoma. The most frequent surgery was lumpectomy (55.7%); 39.4% were G3, 18.6% intraductal component >25% and only 22% had negative margins. RESULTS With a mean follow-up of 85 months, at 5 and 10 years the OS was 93% and 88%, DFS 92% and 89%, and LR 3.6% and 5.3%, respectively. For LR, the risk factors were carcinoma in situ, N+ and involved margins, whereas for metastasis, the risk factors were T2 tumours, stage III, N+ and the presence of local recurrence. CONCLUSIONS HDR-BT boost in one fraction is an effective, simple and safe method for reducing LR. The outpatient setting and shorter treatment duration represent undeniable advantages.

Cite this paper

@article{Prez2012EarlystageBC, title={Early-stage breast cancer conservative treatment: high-dose-rate brachytherapy boost in a single fraction of 700 cGy to the tumour bed.}, author={Aurora Rodr{\'i}guez P{\'e}rez and Pilar Mar{\'i}a Samper Ots and Mar{\'i}a Concepci{\'o}n L{\'o}pez Carrizosa and Jos{\'e} Ferm{\'i}n P{\'e}rez-Regadera G{\'o}mez and Jos{\'e} Zapatero Ortu{\~n}o and Juan de Dios S{\'a}ez Garrido and Manuel Joaqu{\'i}n Mart{\'i}n de Miguel}, journal={Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico}, year={2012}, volume={14 5}, pages={362-8} }